CClinicalTrials.gg
CompletedNCT04757168SCARPACEUpdated Jun 1, 2026

Changes in Regional and Global Cardiac Contractility After Stimulation in Scar Zone With the NOGA System

An interventional study of NOGA TM probe in Myocardial Infarction, sponsored by University Hospital, Toulouse. Completed at 1 site in France. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-06-01.

Sponsored by University Hospital, Toulouse · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Study summary

Despite a decrease in voltage amplitude in post-infarction scar areas, greater voltage amplitudes are sometimes observed at the time of local extrasystoles mechanically induced by catheters.

However, no study has investigated whether these electrical changes are associated with mechanical changes in local contractility.

However, the voltage is closely correlated to the local contractile function as evidenced by the use of the NOGA system.

02

Conditions studied

  • Myocardial Infarction

Keywords

  • stimulation in cardiac scar area
03

In context

Myocardial Infarction

2,744 studies on the registry are indexed under Myocardial Infarction; 418 are open to participants now.

This study's enrollment of 10 is below the median of 148 across 1,595 interventional studies indexed under Myocardial Infarction.

Browse Myocardial Infarction studies →

Lead sponsor

University Hospital, Toulouse is the lead sponsor of 794 studies on the registry; 214 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

- Patients who should undergo ventricular tachycardia (VT) ablation after a myocardial infarction according to current recommendations, namely: patients with ischemic heart disease (ICD) and with episodes of sustained ventricular tachycardia responsible for internal electric shocks by the implantable automatic defibrillator (ICD) (grade IB recommendation)

OR

  • patients with an MIC and an ICD, presenting a first episode of sustained ventricular tachycardia (grade IIa, B recommendation)
  • Affiliated with a social protection scheme
  • Having signed an informed consent

Exclusion criteria

Exclusion Criteria:

  • Contraindication or non-indication for ventricular tachycardia ablation
  • Women who are pregnant or of childbearing age and without contraception, breastfeeding women
  • Patients without ischemic heart disease
  • Patients under guardianship, curatorship or legal protection.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    NOGA TM probe

    Device: NOGA TM probe

Interventions

  • DeviceNOGA TM probe

    Each subject will be his own witness since the linear local shortening (LLS) will be measured successively in all patients before, then after stimulation of the scar zone (comparison of LLS measured in sinus rhythm then during stimulation in the scar zone for each patient. Each subject being his own witness and the two recordings being made a few minutes apart, during the same procedure.

06

What researchers measure

Primary outcomes

  1. Evolution of LLS (linear local shortening) via the NOGATM system in percentage

    Study the change in percentage of LLS during stimulation in a post-infarction scar zone identified by voltage mapping of the left ventricle with the NOGA system, compared to LLS in the same zone measured in atrial stimulation

    Time frame: 1month

Secondary outcomes

  1. Evolution of global systolic function: left ventricular ejection fraction

    Compare the left ventricular ejection fraction (in percentage) during stimulation in a scar area compared to a normal rhythm

    Time frame: 1month

  2. Evolution of the global systolic function: integral time velocity under aortic Translation results Evolution of the global systolic function: integral time velocity under aortic

    Compare the integral time velocity under aortic (in centimeter) during stimulation in a scar area compared to a normal rhythm

    Time frame: 1month

  3. Evolution of the global systolic function: strain longitudinal global

    Compare the strain longitudinal global(in percentage) during stimulation in a scar area compared to a normal rhythm

    Time frame: 1month

07

Study locations

1 site
  • ROLLIN Anne
    Toulouse, CHU de Toulouse 31059, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04757168
Lead sponsor
University Hospital, Toulouse
Responsible party
Sponsor
First posted
Feb 17, 2021
Start date
Feb 23, 2022
Primary completion
Jan 26, 2024
Completion
Jan 26, 2024
Last update
Jun 1, 2026

Study contacts

Anne ROLLIN, MD
principal investigator · University Hospital, Toulouse

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion